Abstract 818
Background
The incidence of breast cancer increases with age with approximately 1800 cases per year in the UK occuring in over 90-year olds. We sought to determine the incidence of new breast cancer diagnoses in this subgroup and examine our practice in the management of these women.
Methods
A retrospective case-note review was performed on 32 patients aged 90 years and over, diagnosed with non-metastatic invasive breast cancer between 2007 and 2017. Clinicopathological data was collected on patients’ cancers, co-morbidities, treatment, recurrence and survival.
Results
Median age at diagnosis was 90 years (range 90-99). Median number of comorbidities was 2 (range 0-6). Mean tumour size was 35mm (range 5-85). 11 cancers (34%) were ER negative and 2 (6%) HER2 positive. 12 cancers (38%) were grade 3 at presentation and 12 had positive axillary lymph node metastases. Twenty-seven (84%) patients underwent a mastectomy, including one bilateral, and five (16%) patients had wide local excision. No patients suffered significant complications in the immediate post-operative period. Twenty-one patients (66%) had adjuvant radiotherapy. No patients underwent adjuvant chemotherapy. Eight patients (25%) developed local or distant recurrence and twenty-one patients (66%) died by the end of the study collection period. Mean disease free survival was 46.4 months (95% CI 31.1-61.7 months) and mean overall survival was 45 months (95% CI 31.7-59.7 months).
Conclusions
Optimal management for older patients is achieved by the co-evaluation of the life expectancy, co-morbidities, and the treatment benefit/risk ratio. Our data suggests that treating older patients with focused surgical and adjuvant treatment is appropriate, however further age-adjusted data is required to standardise care in this subgroup.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pennine Acute Hospitals NHS Trust.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5063 - Does Nutritional Status Affect Treatment Tolarability, Response and Survival in Metastatic Gastric Cancer Patients? Results of Prospective Multicenter Study
Presenter: Senem Karabulut
Session: Poster Display session 2
Resources:
Abstract
2717 - Ramucirumab use in patients with Advanced Gastric Cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study
Presenter: Federico Longo Munoz
Session: Poster Display session 2
Resources:
Abstract
3187 - Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor: Exploratory analysis in the patients who were enrolled in JCOG0705/KGCA01 phase III trial (REGATTA) and could continue chemotherapy
Presenter: Takaki Yoshikawa
Session: Poster Display session 2
Resources:
Abstract
4765 - A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab based therapy
Presenter: Qian Li
Session: Poster Display session 2
Resources:
Abstract
3500 - Randomised phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma (SEED)
Presenter: Peter Petersen
Session: Poster Display session 2
Resources:
Abstract
5197 - Ramucirumab in the treatment of refractory metastatic gastric cancer: results from the RamSelGa trial.
Presenter: Alexey Tryakin
Session: Poster Display session 2
Resources:
Abstract
2011 - Regorafenib in combination with Paclitaxel for beyond first-line treatment of advanced esophagogastric cancer (REPEAT): a phase Ib trial with expansion cohort
Presenter: Mohammed Khurshed
Session: Poster Display session 2
Resources:
Abstract
2117 - The relationship between the survival and fixed dosing of S-1 in advanced gastric cancer patients by pooled analysis using individual data from four Japanese randomized phase III trials
Presenter: Wataru Ichikawa
Session: Poster Display session 2
Resources:
Abstract
2669 - A Phase 1b Study of Oraxol in Combination with Ramucirumab in Patients with Gastric or Esophageal Cancers who failed previous chemotherapy
Presenter: Ming Huang Chen
Session: Poster Display session 2
Resources:
Abstract
3240 - Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): an analysis of the TAGS study
Presenter: Maria Alsina
Session: Poster Display session 2
Resources:
Abstract